Scientific Advisors

Scientific Advisors and Principal Investigators

Douglas Blayney, M.D.
Professor of Medicine (Oncology), Stanford University

Douglas Blayney, M.D. is the Principal Investigator for Study 105 and Study 106.

Dr. Blayney is a Professor of Medicine (Oncology) at Stanford University and former Medical Director of Stanford Cancer Center. He is a founding member and former board member of the NCCN Guidelines for neutropenia management in US, former president of the American Society of Clinical Oncology (ASCO) and has served on the Food and Drug Administration’s Oncologic Drugs Advisory Committee.

Jeffrey Crawford, M.D.
Professor of Medicine, Duke University

Jeffrey Crawford, M.D. is the DSMB Chairman for Study 105 and Study 106.

Dr. Crawford is a Professor of Medicine at Duke University.  He is the Chairman of NCCN guidelines for neutropenia management in the U.S. and was the lead investigator of the U.S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen), which received approval from Food and Drug Administration in 1991.

Yuankai Shi, M.D.
Associate Dean, Cancer Hospital of Chinese Academy of Medical Sciences

Yuankai Shi, M.D. is the Principal Investigator for Study 105 and Study 106 in China.

Dr. Shi is the Associate Dean and Director of Oncology at Cancer Hospital of Chinese Academy of Medical Sciences and Associate Director of the Chinese Medical Association Hematology Branch.  He is the Chairman of the NCCN guidelines for neutropenia management in China.

David Ettinger, M.D.
Professor of Oncology, John Hopkins University

David S. Ettinger, M.D. is the SAB Member for Study 103.

Dr. Ettinger is a Professor of Oncology at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is also a professor of medicine, otolaryngology, head and neck surgery, gynecology and obstetrics, and radiation oncology and molecular radiation sciences. He is the Chairman of NCCN guideline for NSCLC and Board of Directors of NCCN guideline.

Yan Sun, M.D.
Director of GCP Center at Cancer Hospital of Chinese Academy of Medical Sciences

Yan Sun, M.D. is the Principal Investigator for Study 103 in China.

Dr. Sun is the Director of GCP Center at Cancer Hospital of Chinese Academy of Medical Sciences.  He is the co-founder of the Steering Committee of the Chinese Society of Clinical Oncology (CSCO).  He is also the Chairman of the NCCN guidelines for NSCLC in China.

Klaus Ley, M.D.
Professor and Division Head of Inflammation Biology, La Jolla Institute

Klaus Ley, M.D. is a reknowned KOL of Neutropenia Mechanism.

Dr. Ley is a Professor and Division Head of Inflammation Biology at La Jolla Institute.  He has over 30 years of experience in neutrophil research and has published more than 300 papers in peer-review journals and writes review articles on neutrophils for Science Magazine.